Neurensin-2 is a negative regulator of CB1 receptor
Authors:
Open Access
- 3 October 2025
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 242 (Pt 4) , 117382
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Technology, Israel (0004943)
- HORIZON EUROPE European Research Council
- European Research Council
- Gonzaga University
- Hebrew University of Jerusalem
- Neubauer Family Foundation
This publication has 121 references indexed in Scilit:
- Alterations of Sensory-related Functional Brain Network Connectivity in Nrsn2 Homozygous Knockout MicePhenomics, 2024
- Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventionsWorld Psychiatry, 2023
- Regulation of the Hypothalamic‐Pituitary‐Adrenocortical Stress ResponseComprehensive Physiology, 2016
- Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/Akt/mTOR Pathway in Hepatocellular CarcinomaDigestive Diseases and Sciences, 2015
- Epigenetic Mechanisms of DepressionJAMA Psychiatry, 2014
- Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampusHippocampus, 2007
- A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major DepressionArchives of General Psychiatry, 2006
- Effects of chronic stress on hippocampal long‐term potentiationHippocampus, 2002
- Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disordersDepression and Anxiety, 2000
- Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publicationLife Sciences, 1995